AZ-UNIVERSAL-ELECTRONICS
12.7.2022 09:17:06 CEST | Business Wire | Press release
Universal Electronics Inc. (UEI) (NASDAQ:UEIC), the world leader in universal control technology for entertainment and smart home, at the 2022 RDK Tech Summit has announced the release of two new voice remotes for RDK . RDK is one of the leading broadband and pay-tv platforms for the cable industry, with the support of hundreds of partner companies and deployed by more than 30 operators.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220711005949/en/
UEI has shipped over 75 million RDK remote controls to date, with leading operators around the globe, making UEI a market leader in RDK control solutions.
In 2017, the National Academy of Television Arts & Sciences awarded UEI a Technology & Engineering Emmy® Award for its contribution to “Contextual Voice Navigation for Discovering and Interacting with TV Content,” recognizing UEI’s innovator role in the development of the RDK platform.
With the introduction of two new remote-control designs, UEI is expanding its footprint to make it simple for the operators in the RDK community to expand their offering with features that consumers have come to expect from pay-tv services, such as voice control and universal operation of TV sets regardless of the brand.
UEI is collaborating closely with the RDK community to integrate voice and universal control as part of the RDK Accelerator Program – an initiative launched by the RDK community to make it easier for operators to adopt the RDK platform and launch products. UEI’s new RDK remotes serve the same purpose: Since the remotes are pre-integrated, operators can pick one and rest assured it will work with any RDK Accelerator set-top box, relieving them of tedious integration effort and ensuring a short time to market.
Steve Gutman, SVP of Global Sales for Video Service Providers at UEI, said: “We are looking forward to helping customers around the world on the RDK platform to include advanced convenience features such as voice control and automated set-up of their TV and audio devices including soundbars and AV receivers.”
The two new RDK platform remotes UEI is launching at RDK Summit are named “UEI Tatlow” and “UEI Logan .” “UEI Tatlow” is a high-performance voice remote with a premium keypad and optional full backlight, making it easy for people to use it in the dark. “UEI Logan” is a premium voice remote with a unique look and feel including a unibody keypad that is easy to clean.
Both remotes are designed to control live, recorded, and on-demand TV as well as streaming video, and are optionally equipped with QuickSet, the world’s only automated set-up and control experience for home entertainment and smart home devices.
To schedule a meeting with us at RDK Summit visit here
About Universal Electronics Inc.
Universal Electronics Inc. (NASDAQ: UEIC), the global leader in wireless universal control solutions for home entertainment and smart home devices; designs, develops, manufactures, ships and supports hardware and software control and sensor technology solutions. UEI partners with many Fortune 500 customers, including Comcast, Vivint Smart Home, Samsung, LG, Sony, and Daikin to serve video, telecommunications, security service providers, television, smart home, and HVAC system manufacturers. For over 35 years, UEI has been pioneering breakthrough innovations such as voice control and QuickSet cloud, the world’s leading platform for automated set-up and control of devices in the home. For more information visit www.uei.com
About RDK Management:
RDK Management is an open-source consortium that manages RDK for the global community. RDK is an open-source software platform for the connected home that standardizes core functions used in broadband, video, and IoT devices. It enables operators to manage their devices; control their business models; and customize their apps, UIs and data analytics to improve the customer experience and drive business results. The RDK community is comprised of more than 500 companies including: CPE manufacturers, SoC vendors, software developers, system integrators, and service providers. For more information on the tools, training, and events provided by RDK Management, please visit: www.rdkcentral.com .
All trademarks appearing herein are the property of their respective owners.
Quickset®
is a
trademarks of Universal Electronics Inc.
Safe Harbor Statement
This press release contains forward-looking statements that are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting something other than historical fact are intended to identify forward-looking statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development, delivery and market acceptance of products and technologies identified in this release; the purchasing by UEI customers of the UEI RDK products identified in this release in the quantities anticipated by management; the continued penetration and growth of UEI voice recognition technology and other products and consumer technologies identified in this release; and other factors described in UEI’s filings with the Securities and Exchange Commission. The actual results that UEI achieves may differ materially from any forward-looking statement due to such risks and uncertainties. UEI undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220711005949/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom